Last reviewed · How we verify
JS006 as Monotherapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
JS006 as Monotherapy (JS006 as Monotherapy) — Shanghai Junshi Bioscience Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| JS006 as Monotherapy TARGET | JS006 as Monotherapy | Shanghai Junshi Bioscience Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- JS006 as Monotherapy CI watch — RSS
- JS006 as Monotherapy CI watch — Atom
- JS006 as Monotherapy CI watch — JSON
- JS006 as Monotherapy alone — RSS
Cite this brief
Drug Landscape (2026). JS006 as Monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/js006-as-monotherapy. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab